Loading…
The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery
Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service del...
Saved in:
Published in: | AIDS and behavior 2023-11, Vol.27 (11), p.3755-3766 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73 |
container_end_page | 3766 |
container_issue | 11 |
container_start_page | 3755 |
container_title | AIDS and behavior |
container_volume | 27 |
creator | Henderson, Mary Schmidt, Heather-Marie A Chitembo, Lastone Peralta, Hortencia Alaama, Ahmed S Johnson, Cheryl Baggaley, Rachel Schaefer, Robin |
description | Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes. |
doi_str_mv | 10.1007/s10461-023-04093-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10589125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2879462446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEoqXwAiyQJTZlEfAltmM2qJpOL1IFgyhsLcc56bjKxMFO0s5b9RFxmFIuCyRL9tH_nd_nSH-WvST4LcFYvosEF4LkmLIcF1ixnDzK9gmXLGeUF4_TGyucSyL4XvYsxmuMsRJSPc32mGSciJLvZ3eXa0An4zAGQL5BqwD58rb3ca5XwffrbWtuXUSHq7BcvUGND-js_NvMTdANznfv0RE6bX1lWvR5NK0bzOAmQAvfxbGdC9-hdJLX5GoIaAUh9mBnKM7CR7iZxXq0Q0Smq9GxaxoIs7kZoEZfIEzOAjqGNrWE7fPsSWPaCC_u74Ps68nycnGWX3w6PV8cXeS2kHzIS0GtEFRarhpiZVHJWllmalXRZF9TwqtKlVaoqjKSUFw2JVdFiYUUgpNasoPsw863H6sN1DYNFEyr--A2Jmy1N07_rXRura_8pAnmpSKUJ4fDe4fgv48QB71x0ULbmg78GDUtqSoY4Zwk9PU_6LUfQ5f2S5RUhaBFIRJFd5QNPsYAzcM0BOs5EXqXCJ0SoX8mQs_Wr_7c46HlVwQSwHZATFJ3BeH33_-x_QEk2MQQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2879462446</pqid></control><display><type>article</type><title>The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery</title><source>Criminology Collection</source><source>Social Science Premium Collection</source><source>Springer Nature</source><source>Sociology Collection</source><source>Sociological Abstracts</source><creator>Henderson, Mary ; Schmidt, Heather-Marie A ; Chitembo, Lastone ; Peralta, Hortencia ; Alaama, Ahmed S ; Johnson, Cheryl ; Baggaley, Rachel ; Schaefer, Robin</creator><creatorcontrib>Henderson, Mary ; Schmidt, Heather-Marie A ; Chitembo, Lastone ; Peralta, Hortencia ; Alaama, Ahmed S ; Johnson, Cheryl ; Baggaley, Rachel ; Schaefer, Robin</creatorcontrib><description>Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.</description><identifier>ISSN: 1090-7165</identifier><identifier>EISSN: 1573-3254</identifier><identifier>DOI: 10.1007/s10461-023-04093-1</identifier><identifier>PMID: 37351685</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antiretroviral drugs ; Cisgender ; Clients ; COVID-19 ; Digital video recorders ; Disease prevention ; Familiarity ; Guidelines ; Health Psychology ; Health services ; HIV ; Human immunodeficiency virus ; Infectious Diseases ; Medicine ; Medicine & Public Health ; Original Paper ; Prevention ; Prophylaxis ; Prostitution ; Public Health ; Sex workers ; Sexually transmitted diseases ; STD</subject><ispartof>AIDS and behavior, 2023-11, Vol.27 (11), p.3755-3766</ispartof><rights>World Health Organization 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. World Health Organization.</rights><rights>World Health Organization 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>World Health Organization 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73</citedby><cites>FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73</cites><orcidid>0000-0003-4733-4692</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2879462446/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2879462446?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,21376,21394,21395,27344,27924,27925,33611,33612,33769,33770,33774,34530,34531,43733,43814,44115,74221,74310,74639</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37351685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henderson, Mary</creatorcontrib><creatorcontrib>Schmidt, Heather-Marie A</creatorcontrib><creatorcontrib>Chitembo, Lastone</creatorcontrib><creatorcontrib>Peralta, Hortencia</creatorcontrib><creatorcontrib>Alaama, Ahmed S</creatorcontrib><creatorcontrib>Johnson, Cheryl</creatorcontrib><creatorcontrib>Baggaley, Rachel</creatorcontrib><creatorcontrib>Schaefer, Robin</creatorcontrib><title>The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery</title><title>AIDS and behavior</title><addtitle>AIDS Behav</addtitle><addtitle>AIDS Behav</addtitle><description>Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.</description><subject>Antiretroviral drugs</subject><subject>Cisgender</subject><subject>Clients</subject><subject>COVID-19</subject><subject>Digital video recorders</subject><subject>Disease prevention</subject><subject>Familiarity</subject><subject>Guidelines</subject><subject>Health Psychology</subject><subject>Health services</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Paper</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Prostitution</subject><subject>Public Health</subject><subject>Sex workers</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><issn>1090-7165</issn><issn>1573-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>BGRYB</sourceid><sourceid>BHHNA</sourceid><sourceid>HEHIP</sourceid><sourceid>M0O</sourceid><sourceid>M2S</sourceid><recordid>eNp9kstu1DAUhiMEoqXwAiyQJTZlEfAltmM2qJpOL1IFgyhsLcc56bjKxMFO0s5b9RFxmFIuCyRL9tH_nd_nSH-WvST4LcFYvosEF4LkmLIcF1ixnDzK9gmXLGeUF4_TGyucSyL4XvYsxmuMsRJSPc32mGSciJLvZ3eXa0An4zAGQL5BqwD58rb3ca5XwffrbWtuXUSHq7BcvUGND-js_NvMTdANznfv0RE6bX1lWvR5NK0bzOAmQAvfxbGdC9-hdJLX5GoIaAUh9mBnKM7CR7iZxXq0Q0Smq9GxaxoIs7kZoEZfIEzOAjqGNrWE7fPsSWPaCC_u74Ps68nycnGWX3w6PV8cXeS2kHzIS0GtEFRarhpiZVHJWllmalXRZF9TwqtKlVaoqjKSUFw2JVdFiYUUgpNasoPsw863H6sN1DYNFEyr--A2Jmy1N07_rXRura_8pAnmpSKUJ4fDe4fgv48QB71x0ULbmg78GDUtqSoY4Zwk9PU_6LUfQ5f2S5RUhaBFIRJFd5QNPsYAzcM0BOs5EXqXCJ0SoX8mQs_Wr_7c46HlVwQSwHZATFJ3BeH33_-x_QEk2MQQ</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Henderson, Mary</creator><creator>Schmidt, Heather-Marie A</creator><creator>Chitembo, Lastone</creator><creator>Peralta, Hortencia</creator><creator>Alaama, Ahmed S</creator><creator>Johnson, Cheryl</creator><creator>Baggaley, Rachel</creator><creator>Schaefer, Robin</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7T2</scope><scope>7U3</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AM</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>BHHNA</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HEHIP</scope><scope>K7.</scope><scope>K9.</scope><scope>KB0</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4733-4692</orcidid></search><sort><creationdate>20231101</creationdate><title>The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery</title><author>Henderson, Mary ; Schmidt, Heather-Marie A ; Chitembo, Lastone ; Peralta, Hortencia ; Alaama, Ahmed S ; Johnson, Cheryl ; Baggaley, Rachel ; Schaefer, Robin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antiretroviral drugs</topic><topic>Cisgender</topic><topic>Clients</topic><topic>COVID-19</topic><topic>Digital video recorders</topic><topic>Disease prevention</topic><topic>Familiarity</topic><topic>Guidelines</topic><topic>Health Psychology</topic><topic>Health services</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Paper</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Prostitution</topic><topic>Public Health</topic><topic>Sex workers</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henderson, Mary</creatorcontrib><creatorcontrib>Schmidt, Heather-Marie A</creatorcontrib><creatorcontrib>Chitembo, Lastone</creatorcontrib><creatorcontrib>Peralta, Hortencia</creatorcontrib><creatorcontrib>Alaama, Ahmed S</creatorcontrib><creatorcontrib>Johnson, Cheryl</creatorcontrib><creatorcontrib>Baggaley, Rachel</creatorcontrib><creatorcontrib>Schaefer, Robin</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Social Services Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Criminology Collection</collection><collection>Sociological Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Sociology Collection</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Criminal Justice Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henderson, Mary</au><au>Schmidt, Heather-Marie A</au><au>Chitembo, Lastone</au><au>Peralta, Hortencia</au><au>Alaama, Ahmed S</au><au>Johnson, Cheryl</au><au>Baggaley, Rachel</au><au>Schaefer, Robin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery</atitle><jtitle>AIDS and behavior</jtitle><stitle>AIDS Behav</stitle><addtitle>AIDS Behav</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>27</volume><issue>11</issue><spage>3755</spage><epage>3766</epage><pages>3755-3766</pages><issn>1090-7165</issn><eissn>1573-3254</eissn><abstract>Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37351685</pmid><doi>10.1007/s10461-023-04093-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4733-4692</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1090-7165 |
ispartof | AIDS and behavior, 2023-11, Vol.27 (11), p.3755-3766 |
issn | 1090-7165 1573-3254 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10589125 |
source | Criminology Collection; Social Science Premium Collection; Springer Nature; Sociology Collection; Sociological Abstracts |
subjects | Antiretroviral drugs Cisgender Clients COVID-19 Digital video recorders Disease prevention Familiarity Guidelines Health Psychology Health services HIV Human immunodeficiency virus Infectious Diseases Medicine Medicine & Public Health Original Paper Prevention Prophylaxis Prostitution Public Health Sex workers Sexually transmitted diseases STD |
title | The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A37%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Future%20of%20Pre-Exposure%20Prophylaxis%20(PrEP)%20for%20HIV%20Prevention:%20A%20Global%20Qualitative%20Consultation%20on%20Provider%20Perspectives%20on%20New%20Products%20and%20Differentiated%20Service%20Delivery&rft.jtitle=AIDS%20and%20behavior&rft.au=Henderson,%20Mary&rft.date=2023-11-01&rft.volume=27&rft.issue=11&rft.spage=3755&rft.epage=3766&rft.pages=3755-3766&rft.issn=1090-7165&rft.eissn=1573-3254&rft_id=info:doi/10.1007/s10461-023-04093-1&rft_dat=%3Cproquest_pubme%3E2879462446%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-862c6627c59f1c74b7d9c3ad9b2ffed215bb98c69bba71208f859480676651d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2879462446&rft_id=info:pmid/37351685&rfr_iscdi=true |